Skip To Main Content
Xiaoying Li on Muck Rack

Xiaoying Li

As seen in: Allergy - European Journal of Allergy and Clinical Immunology, Color Research & Application, Nature, Wiley Online Library, PLOS, ScienceDirect, BMJ Open, Frontiers, MDPI, Taylor & Francis Online and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Xiaoying

Contact Xiaoying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Sintilimab plus Bevacizumab biosimilar IBI305 and chemotherapy as a first-line treatment in advanced gastric or gastroesophageal junction adenocarcinoma (SBAGA): a single-arm, phase Ib/II study

|
By Mo Cheng, Pengfei Zhang, Qiancheng Hu, Jitao Zhou, Ruihong Dai, Wenke Li, Jing Wei, Menghui Xu, Yanna Lei, Xiaoying Li, Xiufeng Zheng, Qian Huang, Zhiping Li, Bo Zhang, Wen Zhuang, Zhixin Chen, Xiaolong Chen, Chaoyong Shen, Weihan Zhang, Kai Liu, Linyong Zhao, Xiaonan Yin, Zhaolun Cai, Yuan Yin, Ji Chen, Chunjuan Liu, Deying Kang, Mojin Wang, Hongfeng Gou, Kun Yang, Jiankun Hu, Feng Bi, Ming Liu Verified, Boqiang Peng
| Nature Verified
Abstract Adding anti-PD-1 or anti-VEGF therapy to chemotherapy improves survival in patients with advanced gastric cancer, yet outcomes remain poor. This Phase Ib/II trial aimed to evaluate the efficacy and safety of combining sintilimab, the bevacizumab biosimilar IBI305, and CapeOX chemotherapy as a first-line treatment for patients with HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma (GA/GEJA).
Open in Who Shared Issue with article?

qHBsAg Trajectories with Peg-IFNα-2b Add-on Therapy in Nucleos(t)ide Analog-experienced HBeAg-positive Chronic Hepatitis B

|
By Kezhen Hu, Yanzhen Bi, Xiaoying Li
| Xia & He Publishing Inc. Verified
HBsAg loss is a preferred treatment endpoint for functional cure in chronic hepatitis B (CHB), yet it remains uncommon within finite treatment durations, particularly under long-term nucleos(t)ide analogs (NAs) therapy. Pegylated interferon alpha-2b (Peg-IFNα-2b) can increase the probability of HBsAg decline and loss in selected patients; however, in small real-world cohorts, the limited number of HBsAg loss events often leads to imprecise estimates and uncertainty.
Open in Who Shared Issue with article?

Stakeholder Conflicts in Low-Carbon Tourism: A Process-Oriented Framework

|
By Panpan Sun, Xiaoying Li, Songshan Huang
| Taylor & Francis Online
ABSTRACT Low-carbon tourism initiatives frequently generate stakeholder conflicts, even when sustainability goals are widely shared. This study examines how such conflicts arise and propagate in heritage tourism, using Quanzhou Ancient City, China, as the focal case. Findings show that government officials, tourism operators, residents, and tourists hold divergent cognitive, emotional, and behavioural orientations toward low-carbon policies.
Open in Who Shared Issue with article?
See all 113 licensed articles (129 Total)